The Effect of Non-Surgical Periodontal Therapy on Glycemic Control and Bacterial Levels in a Mexican-American Population With Type 2 Diabetes

January 14, 2013 updated by: Isabel Gay, The University of Texas Health Science Center, Houston

The Effect of Non-Surgical Periodontal Therapy on Glycemic Control and Bacterial Levels in a Mexican-American Population With Type 2 DiabetesS

Type 2 diabetes mellitus (T2DM) has become a significant pandemic with more than 7% of the population in the United States affected. Moreover, up to one-third of these individuals may not be aware of the diagnosis and, are not involved in treatment. In the Mexican-American population, prevalence rates may be up to 50%. Contributing factors such as poor education, low household income, language barriers and restricted access to medical services may increase this prevalence. The association between periodontal disease and diabetes has been well documented; however, interventional studies have resulted in conflicting conclusions on improvements in glycemic control following periodontal therapy.

Diabetes and periodontal disease share common pathways in pathogenesis, such as their polygenic nature and immunoregulatory dysfunction. To answer these questions, we, the investigators, propose this randomized controlled trial designed to elucidate how treatment of periodontal disease can be used for preventive and therapeutic purposes in a diabetic population as well as to study the role of IL-1 gene cluster polymorphisms as a risk factor for the presence of periodontitis in a Hispanic T2DM population. Our central hypothesis is that the Mexican-American T2DM population in Texas is at risk for an increased presence and severity of periodontal disease due to the presence of Il-1 gene cluster polymorphisms; furthermore we suggest that providing non-surgical periodontal therapy to this group will decrease the bacterial load associated with disease and as a consequence, will improve glycemic control as measured by HbA1c values. Our long-term goal is to study risk factors associated with the presence of periodontal disease and to understand how the treatment of periodontal disease can be used for preventive and therapeutic purposes in a Hispanic type 2 diabetic population.

Study Overview

Study Type

Interventional

Enrollment (Actual)

134

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Texas
      • Houston, Texas, United States, 77030
        • The University of Texas Health Science Center Houston, Dental Branch

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • At least 18 years old
  • Diagnosed type 2 diabetes mellitus
  • Existence of moderate to severe periodontitis as defined by the American Academy of Periodontology
  • In good general health - able to undergo the proposed therapy without compromise to existing health
  • Demonstrated ability to read and understand written Spanish or English without the aid of ad-hoc interpretation by a third party
  • Demonstrated ability to understand the proposed therapy and possible outcome
  • Demonstrated willingness to comply with all protocol requirements as outlined in the informed consent document
  • Willingness/ability to sign an informed consent document for their own inclusion in the study
  • Hispanic origin as confirmed by patient records

Exclusion Criteria:

  • Pregnancy at the time of enrollment (Pregnancy test is required for female study participants of child-bearing potential.)
  • Use of antibiotics within last 3 months
  • Immunocompromised health status
  • Other medical conditions that represent a threat to life
  • Osteoporosis
  • Biphosphonates, corticosteroids or behavior alteration medications
  • Historical abuse of alcohol or drugs
  • Use of cigarettes/tobacco products within the past 12 months
  • Mental diseases
  • Any other oral pathology that compromise the patient's medical status
  • Diagnosed type 1 diabetes mellitus (Information will be obtained from the medical records)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: intervention
Therapy
Participants will be instructed to brush their teeth using the modified Bass toothbrushing technique; the use of interproximal hygiene aids such as proximal brush or dental floss will be included. A full mouth scaling and root planning will be performed in 2 appointments (2 hours each) with the use of local anesthesia (typically 2% lidocaine with 1:100,000 epinephrine). In the control group, this treatment will be performed after all the data and samples have been collected and will encompass the last 2visits. Periodontal scaling and root planning treatment has been defined by The American Academy of Periodontology (AAP) as the standard of care for patients with periodontal disease. An ultrasonic instrument, scalers and curettes will be utilized to remove calculus and obtain a smooth root surface. The experimental subjects will be appointed 1 week later to complete the scaling and root planning procedure

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
HbA1c percentage
Time Frame: At baseline and 120 days after treatment
At baseline and 120 days after treatment

Secondary Outcome Measures

Outcome Measure
Time Frame
microbial burden
Time Frame: Baseline and 120 days after therapy
Baseline and 120 days after therapy
gene polymorphisms
Time Frame: 120 days after enrolment
120 days after enrolment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Isabel C Gay, DDS, MS, University of Texas Health Science Center Dental Branch
  • Study Chair: James Katancik, DDS, PhD, University of Texas Health Science Center at Houston Dental Branch
  • Study Director: Gena Tribble, PhD, University of Texas Health science Center Houston Dental Branch

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

June 1, 2010

Primary Completion (Actual)

September 1, 2012

Study Completion (Actual)

December 1, 2012

Study Registration Dates

First Submitted

May 20, 2010

First Submitted That Met QC Criteria

May 20, 2010

First Posted (Estimate)

May 21, 2010

Study Record Updates

Last Update Posted (Estimate)

January 15, 2013

Last Update Submitted That Met QC Criteria

January 14, 2013

Last Verified

January 1, 2013

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Type 2 Diabetes Mellitus

Clinical Trials on Periodontal Scaling and root planing

3
Subscribe